Open access
Open access
Powered by Google Translator Translator

Daily Archives: October 27, 2021

Breakthrough infections occur in those with lower antibody levels.

27 Oct, 2021 | 01:45h | UTC

Breakthrough Infections Occur in Those with Lower Antibody Levels, Israeli Study Shows – NIH Director’s Blog

Original study: Covid-19 Breakthrough Infections in Vaccinated Health Care Workers – New England Journal of Medicine

 


FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children ages 5 to 11.

27 Oct, 2021 | 01:48h | UTC

FDA advisory panel recommends Pfizer Covid-19 vaccine be authorized for children – STAT

See also:

Tracking the FDA advisory panel meeting on Covid-19 vaccines for kids – STAT

FDA advisory panel recommends Pfizer vaccine for kids ages 5 to 11 – NPR

 


Mix-and-match COVID vaccines ace the effectiveness test – “No need for brand loyalty”.

27 Oct, 2021 | 01:42h | UTC

Mix-and-match COVID vaccines ace the effectiveness test – Nature

Related:

Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.

Should You Mix and Match Your Booster Shot?

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 


Heterologous AstraZeneca/Pfizer vaccination seems to be associated with increased effectiveness against Covid-19 compared to homologous Pfizer/Pfizer vaccination.

27 Oct, 2021 | 01:44h | UTC

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination – Nature

Related:

Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.

Should You Mix and Match Your Booster Shot?

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Commentary on Twitter

 


What game theory can teach us about controlling pandemics.

27 Oct, 2021 | 01:39h | UTC

What game theory can teach us about controlling pandemics – The BMJ Opinion

 

Commentary on Twitter

 


COVID super-immunity: one of the pandemic’s great puzzles – “People who have previously recovered from COVID-19 have a stronger immune response after being vaccinated than those who have never been infected. Scientists are trying to find out why”.

27 Oct, 2021 | 01:41h | UTC

COVID super-immunity: one of the pandemic’s great puzzles – Nature

 


AGA Clinical Practice Update on Endoscopic Management of Perforations in Gastrointestinal Tract.

27 Oct, 2021 | 01:35h | UTC

AGA Clinical Practice Update on Endoscopic Management of Perforations in Gastrointestinal Tract: Expert Review – Clinical Gastroenterology and Hepatology

 


Bioethics | The suggestion Covid deniers should stay out of Australian public hospitals is appalling.

27 Oct, 2021 | 01:37h | UTC

The suggestion Covid deniers should stay out of Australian public hospitals is appalling – The Guardian

 


UEG Consensus on Functional Dyspepsia.

27 Oct, 2021 | 01:32h | UTC

United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia – UEG Journal

 


RCT: Elective internal mammary node irradiation does not increase disease-free survival or overall survival in most women with node-positive breast cancer.

27 Oct, 2021 | 01:28h | UTC

Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial – JAMA Oncology (free for a limited period)

Commentary: No Survival Benefit for Internal Mammary Node Irradiation in Breast Cancer — Women with medially or centrally located tumors may be candidates, however, says researcher – MedPage Today (free registration required)

 

Commentary on Twitter

 


Opinion | We Need to Ground Truth Assumptions about Gene Therapy – “Researchers, practitioners and patients must balance the discipline’s promise with its reality”.

27 Oct, 2021 | 01:21h | UTC

We Need to Ground Truth Assumptions about Gene Therapy – Nature

 


RCT: Platelet-rich intra-articular plasma injections do not improve symptoms and function in patients with ankle osteoarthritis.

27 Oct, 2021 | 01:26h | UTC

Effect of Platelet-Rich Plasma Injections vs Placebo on Ankle Symptoms and Function in Patients With Ankle Osteoarthritis: A Randomized Clinical Trial – JAMA (free for a limited period)

Related:

RCT: No benefit from platelet-rich plasma injection for patients with debilitating Achilles tendinopathy.

M-A: Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma, and hyaluronic acid for hip osteoarthritis pain

 


RCT: In critically ill patients, an individualized glucose control targeting an ICU patient’s pre-admission usual glycemia did not demonstrate a survival benefit compared to conventional glucose control (targeting glycemia below 180 mg/dL).

27 Oct, 2021 | 01:17h | UTC

Individualised versus conventional glucose control in critically-ill patients: the CONTROLING study—a randomized clinical trial – Intensive Care Medicine

Editorial: The goal of personalized glucose control in the critically ill remains elusive – Intensive Care Medicine

 


Anticoagulants and diabetes agents are among the most frequent causes of emergency department visits attributed to medication harms.

27 Oct, 2021 | 01:15h | UTC

US Emergency Department Visits Attributed to Medication Harms, 2017-2019 – JAMA (link to abstract – $ for full-text)

Commentaries:

Number of emergency room visits for medication harms increases with age – MedicalResearch.com

Blood thinners, diabetes meds among top causes of drug-related ER visits – UPI

 


RCT: Ozanimod as induction and maintenance therapy for ulcerative colitis.

27 Oct, 2021 | 01:19h | UTC

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis – New England Journal of Medicine

 

Commentary on Twitter

 


M-A: The efficacy of pharmacotherapies for the treatment of borderline personality disorder is limited.

27 Oct, 2021 | 01:11h | UTC

Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis – CNS Drugs

 


Podcast: Atopic Dermatitis Pearls.

27 Oct, 2021 | 01:01h | UTC

Atopic Dermatitis Pearls – The Cribsiders

 


Systematic Review: Virtual care in patients with cancer.

27 Oct, 2021 | 01:04h | UTC

Virtual Care in Patients with Cancer: A Systematic Review – Current Oncology

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.